U.S. FDA Approves DARZALEX FASPRO® (daratumumab and hyaluronidasefihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse | Johnson & Johnson

U.S. FDA Approves DARZALEX FASPRO® (daratumumab and hyaluronidasefihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse

12/01/2021

DownloadPDF 182 KB

Multimedia Files:

Questions? Please contact us:

investor-relations@its.jnj.com